Automated quantitative analysis of p53, cyclin D1, Ki67 and pERK expression in breast carcinoma does not differ from expert pathologist scoring and correlates with clinico-pathological characteristics

Cancers

Volumn 4, Issue 3, 2012, Pages 725-742

  Cass, Jamaica D ^a   Varma, Sonal ^b   Day, Andrew G ^c   Sangrar, Waheed ^a   Rajput, Ashish B ^b   Raptis, Leda H ^a   Squire, Jeremy ^a   Madarnas, Yolanda ^b   SenGupta, Sandip K ^b   Elliott, Bruce E ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Automated image analysis; Breast cancer; Clinico pathological parameters; P53 cyclin D1 Ki67 pERK; Tissue microarray

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; TUMOR MARKER;

ACCURACY; ADULT; ARTICLE; AUTOANALYSIS; BREAST CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE; MAJOR CLINICAL STUDY; PATHOLOGIST; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TUMOR VOLUME; VALIDATION PROCESS;

EID: 84866930273     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers4030725     Document Type: Article

References (34)

1. Dancey, J.E.; Chen, H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 2006, 8, 649-659.
2. Sotiriou, C.; Pusztai, L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 2009, 360, 790-800.
3. Camp, R.L.; Neumeister, V.; Rimm, D.L. A decade of tissue microarrays: Progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol. 2008, 26, 5630-5637.
4. Pleşan, D.M.; Georgescu, C.V.; Pǎtranǎ, N.; Pleşan, C.; Stoica, D. Immunohistochemical study of p53 and Ki67 in a group of patients with mammary carcinoma. Rom. J. Morphol. Embryol. 2010, 51, 459-465.
5. Liu, C.; Chen, B.; Zhu, J.; Zhang, R.; Yao, F.; Jin, F.; Xu, H.; Lu, P. Clinical implications for nestin protein expression in breast cancer. Cancer Sci. 2009, 101, 815-819.
6. Cho, E.Y.; Han, J.J.; Choi, Y.L.; Kim, K.M.; Oh, Y.L. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: An immunohistochemical and chromogenic in situ hybridization study. J. Korean Med. Sci. 2008, 6, 1053-1061.
7. Frogne, T.; Laenkholm, A.V.; Lyng, M.B.; Henriksen, K.L.; Lykkesfeldt, A.E. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009, 11, R11.
8. Öhlschlegel, C.; Zahel, K.; Kradolfer, D.; Hell, M.; Jochum, W. HER2 genetic heterogeneity in breast carcinoma. J. Clin. Pathol. 2011, 64, 1112-1116.
9. Ridolfi, R.; Jamehdor, M.; Arber, J. HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach. Mod. Pathol. 2000, 13, 866-873.
10. Bobrovnikova-Marjon, E.; Grigoriadou, C.; Pytel, D.; Zhang, F.; Ye, J.; Koumenis, C.; Cavener, D.; Diehl, J. pERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 2010, 27, 3881-3895.
11. Montagut, C.; Settleman, J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 2, 125-134.
12. Hadzisejdić, I.; Mustać, E.; Jonjić, N.; Petković, M.; Grahovac, B. Nuclear EGFR in ductal invasive breast cancer: Correlation with cyclin-D1 and prognosis. Mod. Pathol. 2010, 3, 392-403.
13. Courjal, F.; Cuny, M.; Simony-Lafontaine, J.; Louason, G.; Speiser, P.; Zeillinger, R.; Rodriguez, C.; Theillet, C. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups. Cancer Res. 1997, 19, 4360-4367.
14. Borrás, C.; Gómez-Cabrera, M.C.; Viña, J. The dual role of p53: DNA protection and antioxidant. Free Radic. Res. 2011, 45, 643-652.
15. Tennis, M.; Krishnan, S.; Bonner, M.; Ambrosone, C.B.; Vena, J.E.; Moysich, K.; Swede, H.; McCann, S.; Hall, P.; Shields, P.; et al. p53 Mutation analysis in breast tumors by a DNA microarray method. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 80-85.
16. Li, X.R.; Liu, M.; Zhang, Y.J.; Wang, J.D.; Zheng, Y.Q.; Li, J.; Ma, B.; Song, X. CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med. Oncol. 2011, 28, 129-134.
17. Millar, E.K.; Graham, P.H.; McNeil, C.M. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br. J. Cancer 2011, 105, 272-280.
18. Turashvili, G.; Leung, S.; Turbin, D.; Montgomery, K.; Gilks, B.; West, R.; Carrier, M.; Huntsman, D.; Aparicio, S. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): Pathologist assessment compared to quantitative image analysis. BMC Cancer 2009, 9, 165-177.
19. Turbin, D.A.; Leung, S.; Cheang, M.; Kennecke, H.; Montgomery, K.; McKinney, S.; Treaba, D.; Boyd, N.; Goldstein, L.; Badve, S. et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: A tissue microarray study of 3,484 cases. Breast Cancer Res. Treat. 2008, 3, 417-426.
20. Bolton, K.L.; Garcia-Closas, M.; Pfeiffer, R.M.; Duggan, M.; Howat, W.; Hewitt, S.; Yang, X.; Cornelison, R.; Anzick, S.; Meltzer, P.; et al. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol. Biomarkers Prev. 2010, 4, 992-999.
21. Rajput, A.; Hu, N.; Varma, S.; Chen, C.H.; Ding, K.; Park, P.C.; Chapman, J.A.; SenGupta, S.K.; Madarnas, Y.; Elliott, B.E.; et al. Immunohistochemical assessment of expression of centromere protein-A (CENPA) in human invasive breast cancer. Cancers 2011, 3, 4212-4227.
22. Parissenti, A.M.; Chapman, J.A.; Kahn, H.J.; Guo, B.; Han, L.; O'Brien, P.; Clemons, M.P.; Jong, R.; Dent, R.; Fitzgerald, B.; et al. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 2010, 119, 347-356.
23. Milde-Langosch, K.; Bamberger, A.M.; Rieck, G.; Grund, D.; Hemminger, G.; Müller, V.; Löning, T. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br. J. Cancer 2005, 12, 2206-2215.
24. Whyte, J.; Bergin, O.; Bianchi, A.; McNally, S.; Martin, F. Key signaling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signaling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res. 2009, 11, 209-222.
25. Torii, S.; Yamamoto, T.; Tsuchiya, Y.; Nishida, E. ERK MAP kinase in G1 cell cycle progression and cancer. Cancer Sci. 2006, 97, 697-702.
26. Whyte, J.; Bergin, O.; Bianchi, A.; McNally, S.; Martin, F. Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res. 2009, 11, 209-223.
27. Agarwal, R.; Gonzalez-Angulo, A.; Myhre, S.; Carey, M.; Lee, J.; Overgaard, J.; Alsner, J.; Stemke-Hale, K.; Lluch, A.; Neve, R.; et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin. Cancer Res. 2009, 11, 3654-3662.
28. Boström, P.; Söderström, M.; Palokangas, T.; Vahlberg, T.; Collan, Y.; Carpen, O.; Hirsimäki, P. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumor grade and other prognostic factors. BMC Res. Notes 2009, 2, 140-148.
29. Caldon, C.; Sutherland, R.; Musgrove, E. Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer. Cell Cycle 2010, 10, 1918-1928.
30. McShane, L.M.; Altman, D.G.; Sauerbrei, W.; Taube, S.E.; Gion, M.; Clark, G.M. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 2006, 2, 229-235.
31. Booy, E.P.; Henson, E.S.; Gibson, S.B. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signaling pathway contributing to cell survival in breast cancer. Oncogene 2011, 30, 2367-2378.
32. Wolff, H.C.; Hammond, M.; Schwartz, J.; Hagerty, K.; Allred, D.; Cote, R.; Dowsett, M.; Fitzgibbons, P.; Hanna, W.; Langer, A.; et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007, 131, 18-43.
33. Hanley, J.A.; McNeil, B.J. The meaning and use of the area under a receiver operating characteristic (Roc) Curve. Radiology 1982, 143, 29-36.
34. Hu, J.X.; Zhao, H.; Zhou, H.H. False discovery rate control with groups. J. Am. Stat. Assoc. 2010, 105, 1215-1227.